2025年地夫可特最新价格是多少钱一盒

The global price system of deflazacort in 2025 shows significant regional differences. The German version sells for about US$83 per box, while the Indian version only costs US$42. The difference is due to various countries' drug regulatory policies, production scale and exchange rate fluctuations. Patients need to choose a purchasing plan based on the treatment cycle, economic ability and drug compliance. At present, deflazacort has not yet been launched in China. Domestic patients need to obtain it through cross-border drug purchase or clinical trials. They need to be wary of the legal risks and drug quality risks caused by illegal drug purchases.

How much is the latest price of deflazacort in 2025?

The price system is significantly affected by R&D cost allocation, production scale effect and market access policy. Patients need to choose a purchasing plan based on the treatment cycle, dose adjustment needs and compliance requirements.

Price of the German version

The German version of deflazacort is produced by Sanofi-Aventis (Switzerland), with a specification of 6 mg × 100 tablets, and a single box price of approximately US$83.

Indian version price

The Indian version of deflazacort is 6mg × 100 tablets, priced at about US$42 per box. This version uses Blister Pack (blister packaging) technology, and the single-tablet dose can be flexibly divided to 0.9mg/kg per day, which is suitable for dosage adjustment in pediatric patients.

Global marketing status of deflazacort

As a third-generation glucocorticoid, deflazacort’s global marketing history is closely related to the expansion of indications. Patients need to pay attention to the drug regulatory policies and medical insurance coverage of various countries.

R&D and initial marketing

Deflazacort was first developed and marketed by the Spanish company Faes Farma in 1990. It was initially used to treat allergic asthma, rheumatoid arthritis and other indications. The drug entered the European market in 1995 and became an off-label drug for the treatment of Duchenne muscular dystrophy (DMD). In 1999, deflazacort was launched in South Korea for the treatment of skin allergies and collagen diseases.

U.S. FDA Approval

On February 9, 2017, the U.S. FDA approved deflazacort to be marketed under the trade name Emflaza for the treatment of DMD patients aged 2 years and above. The drug became the first approved treatment for DMD in the United States. In 2019, Macau Wuzhou Pharmaceutical signed an agency agreement with Faes Farma in the Greater China region and completed the listing registration of Defal in Macau.

Deflazacort medication preparation

Deflazacort medication must strictly follow the scope of indications, dose adjustment principles and contraindication screening. Patients must establish a standardized medication process to avoid treatment interruption or serious adverse reactions due to improper operation.

Preparation for vaccination

Vaccination with live attenuated or live vaccines, including measles, mumps, rubella vaccine (MMR) and varicella vaccine, must be completed 4-6 weeks before using deflazacort. After vaccination, body temperature and local reactions need to be monitored. If fever exceeds 38.5°C or the diameter of redness and swelling at the vaccination site exceeds 5cm, deflazacort medication must be suspended and a doctor must be consulted.

Principles for dose adjustment

The initial dose of deflazacort is 0.9 mg/kg/day, and the maximum dose does not exceed 90 mg/day. For pediatric patients weighing more than 50kg, tablet combination administration is required. When combined with moderate or strong CYP3A4 inhibitors (such as clarithromycin, ketoconazole), the dose needs to be reduced to 1/3 of the usual dose.

Deflazacort is contraindicated in patients with glucocorticoid allergy, systemic infection, recent intestinal anastomosis surgery, renal failure, hypertension, diabetes, osteoporosis, and myasthenia gravis. The safety and effectiveness of this medication for children under 5 years old have not been established, so use it with caution.